[Reactivation of hepatitis B after treatment with CHOP and rituximab].
Fernández Fernández
F J
FJ
de la Fuente Aguado
J
J
Puerta Louro
R
R
Fernández Villaverde
A
A
Soto Ríos
C
C
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D019694:Hepatitis B, Chronic / Q000209:etiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000009:adverse effects; D012008:Recurrence; D000069283:Rituximab; D014750:Vincristine / Q000009:adverse effects
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone